Results 171 to 180 of about 29,283 (270)

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study. [PDF]

Blood Adv
Camus V, Krzisch D, Bruscaggin A, Lévêque E, Viennot M, Fornecker LM, Cheminant M, Bailly S, Morschhauser F, Feugier P, Choquet S, Durot E, Carras S, Delette C, Damaj GL, Waultier-Rascalou A, Lebreton P, Le Du K, Galtier J, Houot R, Morineau N, Laribi K, Lebras L, Oberic L, Amorim S, Bocchetta S, Viailly PJ, Rainville V, Ruminy P, Caillot M, Terzi di Bergamo L, Piffaretti D, Pirosa MC, Salehi M, Forestieri G, Drieux F, Veresezan EL, Traverse-Glehen A, Donzel M, Burel L, Bohers E, Lanic MD, Penther D, Becker S, Decazes P, Tonnelet D, Draye-Carbonnier S, Tilly H, Jardin F, Rossi D, Sesques P.   +50 more
europepmc   +1 more source

Mitochondrial DNA in Tumor Evolution and Heterogeneity: Characteristics, Technological Advances, Applications and Challenges

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review highlights mitochondrial DNA (mtDNA) somatic mutations as an emerging and potent endogenous lineage marker, offering distinct advantages over traditional nuclear genomic (nDNA) approaches. Lineage tracing based on mtDNA mutations has matured into an indispensable tool, providing unprecedented insights into tumor biology and holding ...
Zifeng Ruan, Zihao Chen, Weicheng Yu, Maolei Zhang, Xingguo Liu   +4 more
wiley   +1 more source

A Critical Review of PET/CT Assessment After CAR-T Cell Therapy in Large B-Cell Lymphoma, Limitations of Current Criteria, Emerging Biomarkers, and a Framework for Standardised Evaluation. [PDF]

J Multidiscip Healthc
Jambi LK, Kabrah SM.
europepmc   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

MedComm – Oncology, Volume 5, Issue 3, September 2026.
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley   +1 more source

Detection of Circulating Tumour DNA in Plasma during the Treatment of In-transit Melanoma Metastases with Topical Imiquimod. [PDF]

Acta Derm Venereol
Mansilla-Polo M, Unamuno-Bustos B, Navarro-Blanco F, Pérez-Simó G, Palanca-Suela S, Botella-Estrada R.   +5 more
europepmc   +1 more source

Zea mays Drought‐Overly Sensitive1/TUBA4 Is Wilty3, and Transcriptome Co‐Expression Analysis of Shoot Meristem Mutant Tissues Reveals Wilty2/TUB6:Wi3 Interactions Associated With Stem Vascular Bundle Development

Plant Direct, Volume 10, Issue 9, September 2026.
ABSTRACT Plant vasculature is essential for the transport of water, nutrients, and signaling molecules across organs, while also providing critical mechanical support for growth and development. Disruptions in vascular bundle formation can therefore lead to severe physiological and developmental defects.
Anuradha Dhingra, Indra Adhikari, Christopher D. Rock   +2 more
wiley   +1 more source

Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma. [PDF]

Blood Cancer J
Haider Z, Deleskog Spångberg L, Smedby KE, Krynina O, Jylhä C, Savitcheva I, Lundin E, Palma M, Hansson L, Saft L, Oder B, Lyander A, Hägglund M, Gellerbring A, Johansson M, Nyrén K, Rosenquist R, Wästerlid T, Tham E.   +18 more
europepmc   +1 more source

Breaking the ctDNA sensitivity barrier

, 2017
O estudo da biologia molecular do cancro tem permitido avanços científicos com impacto na prática clínica, mudando o paradigma de abordagem terapêutica convencional, sistémica, para uma abordagem personalizada. No entanto, a caracterização molecular de tumores sólidos só é possível através da biopsia do tecido, uma estratégia altamente invasiva com ...
openaire   +1 more source

A Droplet‐Microarray Platform for Multiplex Profiling of Breast Cancer Exosome Subtypes in Patients’ Blood Plasma Samples

Small, Volume 22, Issue 49, 1 September 2026.
This study presents a droplet‐microarray platform integrated with a DNase I‐assisted MoS2 FRET aptasensor for multiplexed profiling of breast cancer subtypes’ exosomes from patients’ plasma. By targeting HER2, MUC1, and CD44, the system enables sensitive detection and accurate discrimination of luminal A, HER2‐positive, and triple‐negative subtypes ...
Yi Liu, Ruolin Zhang, Jialei Song, Meng Xiao, Yue Meng, Zhiyang Li, Jingyu Shi, Yunyan Tai, Bing Gu, Mo Yang   +9 more
wiley   +1 more source

Circulating tumor DNA in breast cancer: updates from SABCS 2025. [PDF]

J Hematol Oncol
Zhi I, Zou X, Sun M, Chan N, Ko N, Vasan N, Ganesan S, Ma C.   +7 more
europepmc   +1 more source